+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic



Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic



Cns Drugs 18(2): 105-111



In some countries, such as Germany, there has been a move towards the treatment of patients with Parkinson's disease in specialised inpatient units. However, data on patient outcome and the daily costs of antiparkinsonian drugs in these settings are rare. This study was conducted to determine the effect of an inpatient setting (a specialised Parkinson's disease clinic) on drug therapy costs and patient symptoms. This study involved 63 consecutively referred inpatients of a Parkinson's disease clinic. On entry to the clinic, the patients' antiparkinsonian drug regimen was titrated in order to improve their motor function. The daily costs of drug therapy per patient (in 2002 values) were calculated, and the severity of Parkinson's disease symptoms scored via scores on the Unified Parkinson's Disease Rating Scale (UPDRS) and standardised instrumental procedures (peg insertion and tapping), both initially and at the end of the patients' stay in the clinic. The variables between the two evaluation timepoints were compared. The titration of antiparkinsonian drugs was associated with a significant decrease in the symptoms of Parkinson's disease at discharge from the clinic compared with admission (as measured by UPDRS total and subscale scores [all p < 0.001], and, to a lesser extent, by peg insertion and tapping [both p < 0.05]). A significant increase in daily drug costs (an increase of euro14.11 per patient for all drugs and euro12.36 per patient for antiparkinsonian drugs [both p <0.001]) was also observed. The results demonstrate that the symptoms experienced by patients with Parkinson's disease improve after performance of antiparkinsonian drug titration within the setting of a specialised Parkinson's disease clinic. The effect on symptoms was seen most clearly with the UPDRS, although both peg insertion and tapping reflected this improvement to a certain extent. Drug titration resulted in, on average, a doubling of daily drug costs. Future trials are needed to investigate the long-term effects of such a hospital stay on indirect costs associated with treating Parkinson's disease, and on caregiver burden, and also to compare the efficacy of a Parkinson's disease clinic with an outpatient setting.

(PDF emailed within 0-6 h: $19.90)

Accession: 035980076

Download citation: RISBibTeXText

PMID: 14728057

DOI: 10.2165/00023210-200418020-00004


Related references

Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics. Neurorehabilitation 18(3): 271-275, 2003

Costs of drug treatment in Parkinson's disease. Movement Disorders 13(2): 249-254, 1998

Selegiline and the Treatment of Parkinson's Disease: How patients can benefit from drug therapy. Canadian Family Physician Medecin de Famille Canadien 37: 1231-1236, 1991

Drug and treatment costs in Parkinson's disease patients in Sweden. Acta Neurologica Scandinavica 125(2): 142-147, 2012

Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease?. Neuropharmacology 48(7): 984-992, 2005

The Parkinson's Disease Activities of Daily Living Scale: a new simple and brief subjective measure of disability in Parkinson's disease. Clinical Rehabilitation 15(3): 241-246, 2001

Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy. Medizinische Klinik 91(7): 479-485, 1996

Treating patients with Parkinson,s disease is a specialty: Parkinson,s disease - an abundant set of symptoms. Sygeplejersken 74(49): 4-5, 1974

Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. New England Journal of Medicine 340(10): 757-763, 1999

Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1. JAMA Neurology 73(3): 321-328, 2016

Non-oral drug delivery in Parkinson's disease: a summary from the symposium at the 7th International Congress of Parkinson's Disease and Movement Disorders. 10-14 November 2002, Miami, FL, USA. Expert Opinion on PharmacoTherapy 4(4): 595-599, 2003

The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. Parkinsonism and Related Disorders 25: 21-26, 2017

Survey on general knowledge on Parkinson's disease in patients with Parkinson's disease and current clinical practice for Parkinson's disease among general neurologists from Southwest China. Clinical Neurology and Neurosurgery 118: 16-20, 2014

Patient page. Slowing down a "slow" movement disorder: selegiline's benefit in treating Parkinson disease. Neurology 66(8): E28-E29, 2006

Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. Journal of Neurology, Neurosurgery, and Psychiatry 87(11): 1183-1190, 2016